Feb 7, 2022 4:30 pm EST iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
Jan 26, 2022 9:00 am EST iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
Dec 22, 2021 9:25 am EST iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
Dec 21, 2021 9:20 am EST iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
Nov 30, 2021 8:00 am EST ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
Nov 29, 2021 8:45 am EST Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
Nov 17, 2021 4:30 pm EST Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
Nov 15, 2021 4:05 pm EST iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update